关键词:
肿瘤治疗; 急性腹泻; 奥曲肽
Domestic versus imported octreotide in the treatment of acute diarrhea associated with anti-tumor therapy: an analysis of 138 cases
Hong Qiu, Hui-Hua Xiong, Guang-Yuan Hu, Rui Wang, Xi Tang
Hong Qiu, Hui-Hua Xiong, Guang-Yuan Hu,
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Rui Wang,
Department of Oncology, Wuhan No.1 Hospital, Wuhan 430022, Hubei Province, China
Xi Tang,
Department of Oncology, Jingzhou Central Hospital, Jingzhou 434020, Hubei Province, China
Correspondence to
: Guang-Yuan Hu, Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.
[email protected]
Received:
January 11, 2010
Revised:
April 6, 2010
Accepted:
April 13, 2010
Published online:
May 8, 2010
AIM
: To compare the efficacy of domestic and imported octreotide (Sandostatin) in the treatment of acute diarrhea associated with anti-tumor therapy.
METHODS
: One hundred and thirty-eight patients with grade II or III diarrhea were enrolled into the study, of which 66 received Sandostatin treatment, and 72 were given domestic octreotide (100 µg, tid). Therapeutic efficacy was evaluated after a 3-day treatment.
RESULTS
: No significant difference was noted in the complete remission rate of diarrhea between patients treated with Sandostatin and domestic octreotide (75.8%
vs
79.2%,
P
> 0.05). The doses of domestic octreotide used on days 2 and 3 were significantly higher than those of Sandostatin (both
P
< 0.05). The cost-effectiveness value for Sandostatin was significantly higher than that for domestic octreotide (1148.7
vs
507.3,
P
< 0.05).
CONCLUSION
: Domestic octreotide has equivalent efficacy and superior cost-effectiveness to Sandostatin in treating acute diarrhea associated with anti-tumor therapy. Increasing the dose of domestic octreotide is a reasonable choice in the management of grade III diarrhea.
Reichlin S
. Somatostatin and its receptor. Introduction.
Ciba Found Symp
. 1995;
190
:1-6.
[
PubMed
]
[
DOI
]
Prommer EE
. Established and potential therapeutic applications of octreotide in palliative care.
Support Care Cancer
. 2008;
16
:1117-1123.
[
PubMed
]
[
DOI
]
Ashley AC
, Sargent DJ, Alberts SR, Grothey A, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.
Cancer
. 2007;
110
:670-677.
[
PubMed
]
[
DOI
]
Cascinu S
, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.
J Clin Oncol
. 1993;
11
:148-151.
[
PubMed
]
[
DOI
]
Barbounis V
, Koumakis G, Vassilomanolakis M, Demiri M, Efremidis AP. Control of irinotecan-induced diarrhea by octreotide after loperamide failure.
Support Care Cancer
. 2001;
9
:258-260.
[
PubMed
]
[
DOI
]
Cascinu S
, Fedeli A, Fedeli SL, Catalano G. Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin.
Oncology
. 1994;
51
:70-73.
[
PubMed
]
[
DOI
]
Maroun JA
, Anthony LB, Blais N, Burkes R, Dowden SD, Dranitsaris G, Samson B, Shah A, Thirlwell MP, Vincent MD. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea.
Curr Oncol
. 2007;
14
:13-20.
[
PubMed
]
[
DOI
]
Sanguineti G
, Endres EJ, Parker BC, Bicquart C, Little M, Chen G, Berilgen J. Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer.
Acta Oncol
. 2008;
47
:301-310.
[
PubMed
]
[
DOI
]
Petersenn S
. Efficacy and limits of somatostatin analogs.
J Endocrinol Invest
. 2005;
28
:53-57.
[
PubMed
]
[
DOI
]
